quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:26:00·3d
ANALYSTRating
Candel Therapeutics Inc. logo

Cantor Fitzgerald initiated coverage on Candel Therapeutics

CADL· Candel Therapeutics Inc.
Health Care
Original source

Companies

  • CADL
    Candel Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 20UpdateCantor Fitzgerald-
  • Oct 28UpdateStephens$15.00
  • Sep 3UpdateBofA Securities$7.00
  • Jun 30UpdateH.C. Wainwright$23.00
  • Feb 20UpdateCitigroup$25.00
  • Feb 19UpdateCanaccord Genuity$20.00

Related

  • INSIDER21d
    SEC Form 4 filed by Manning Paul B
  • INSIDER21d
    SEC Form 4 filed by Papa Joseph C
  • INSIDER21d
    SEC Form 4 filed by Loggia Nicoletta
  • PR21d
    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC36d
    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.
  • PR37d
    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
  • SEC42d
    SEC Form S-8 filed by Candel Therapeutics Inc.
  • SEC42d
    SEC Form 10-K filed by Candel Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022